HRTX 8-K 2026-11-09

HERON THERAPEUTICS, INC. /DE/ (HRTX) 8-K dated 2026-11-09 — accession 0001193125-26-452721.

HERON THERAPEUTICS, INC. /DE/ (HRTX) is a biotechnology company listed on US.

HRTX: Heron Therapeutics Announces Third Quarter 2026 Financial Results

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported HRTX revenue for 2025-12-31 was $154.9M. Net income was -$20.2M. Revenue was up 7.4% from 2024-12-31 to 2025-12-31. HRTX currently screens at market cap $332.6M.

Not investment advice. The HRTX SEC hub lists recent forms. The stock page is the research view.